Industrial Real Estate in Philadelphia, PA

Cap rates for industrial properties in Philadelphia vary by submarket, property class, and occupancy levels. The overall Philadelphia market average cap rate is approximately 6.5%. Class A properties typically trade at lower cap rates than value-add opportunities.

Industrial has benefited from structural demand drivers including e-commerce growth (which requires 3x more logistics space than brick-and-mortar retail), supply chain reshoring and nearshoring trends, inventory stockpiling following pandemic-era disruptions, and limited developable land in infill locations. These factors have driven vacancy rates below 4% nationally and pushed rent growth well above historical averages in most markets.

Bulk warehouses are large-scale distribution centers (typically 200,000+ SF) located along major transportation corridors, used for regional storage and distribution. Last-mile facilities are smaller (20,000-150,000 SF), located closer to dense population centers, and serve the final leg of delivery to end consumers. Last-mile properties typically command higher rents per square foot due to land scarcity and proximity to customers but offer lower overall NOI given their smaller footprint.

Philadelphia offers 100-200 basis points higher cap rates than comparable New York assets, providing a meaningful yield premium. The metro benefits from proximity to New York (90 minutes by train) while maintaining its own deep employment base. Life sciences, healthcare, and education institutions provide recession-resistant demand that New York's more finance-dependent economy does not always match. However, Philadelphia's total market liquidity and appreciation potential are more modest than New York.

The University of Pennsylvania, Drexel, Temple, and Jefferson health systems generate enormous research funding that spins off into commercial lab and office demand. University City's uCity Square and Schuylkill Yards developments are adding millions of square feet of purpose-built lab space. The metro is the second-largest cell and gene therapy hub in the US after the Boston-Cambridge corridor. Major pharma companies including GSK, Merck, and AstraZeneca maintain significant operations in the region.